易明医药
(002826)
| 流通市值：31.85亿 | | | 总市值：34.84亿 |
| 流通股本：1.74亿 | | | 总股本：1.91亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 488,983,972.66 | 311,445,583.3 | 148,531,481.16 | 651,883,906.6 |
| 营业收入 | 488,983,972.66 | 311,445,583.3 | 148,531,481.16 | 651,883,906.6 |
| 二、营业总成本 | 435,575,357.61 | 276,759,233.44 | 137,710,650.37 | 622,489,893.1 |
| 营业成本 | 87,288,420.68 | 59,520,527.43 | 29,899,682.84 | 205,252,937.23 |
| 税金及附加 | 9,160,123.89 | 5,921,012.69 | 2,984,869.04 | 12,274,464.69 |
| 销售费用 | 276,945,987.49 | 178,846,734.9 | 87,778,691.76 | 341,227,732.29 |
| 管理费用 | 52,506,455.41 | 30,462,429.74 | 15,816,207.02 | 49,417,529.07 |
| 研发费用 | 9,875,884.83 | 2,236,626.52 | 1,197,352.52 | 15,482,858.58 |
| 财务费用 | -201,514.69 | -228,097.84 | 33,847.19 | -1,165,628.76 |
| 其中:利息费用 | 841,554.28 | 531,319.66 | 200,738.92 | 445,889.7 |
| 其中:利息收入 | 1,074,871.36 | 780,232.57 | 178,542.83 | 1,682,915.88 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 1,603,361.73 | 1,193,874.46 | 147,791.65 | 3,513,562.9 |
| 资产处置收益 | -231,318.41 | -231,283.9 | -231,263.9 | -44,949.62 |
| 资产减值损失(新) | -2,893.59 | -2,893.59 | -2,893.59 | -291,066.14 |
| 信用减值损失(新) | -371,267.19 | -283,632.71 | 119,817.11 | -902,425.79 |
| 其他收益 | 34,920,235.55 | 15,344,079.4 | 10,275,514.1 | 29,832,030.2 |
| 四、营业利润 | 89,326,733.14 | 50,706,493.52 | 21,129,796.16 | 61,501,165.05 |
| 加:营业外收入 | 14,797,108.88 | 222,701.56 | 25,238.3 | 911,853.08 |
| 减:营业外支出 | 1,905,556.09 | 1,764,589.53 | 148,801.91 | 2,037,442.8 |
| 五、利润总额 | 102,218,285.93 | 49,164,605.55 | 21,006,232.55 | 60,375,575.33 |
| 减:所得税费用 | 20,455,014.49 | 11,425,475.91 | 2,077,675.98 | 12,915,577.3 |
| 六、净利润 | 81,763,271.44 | 37,739,129.64 | 18,928,556.57 | 47,459,998.03 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 81,763,271.44 | 37,739,129.64 | 18,928,556.57 | 47,459,998.03 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 81,763,271.44 | 37,557,144.18 | 18,793,851.93 | 45,928,802.86 |
| 少数股东损益 | - | 181,985.46 | 134,704.64 | 1,531,195.17 |
| 扣除非经常损益后的净利润 | 39,947,274.74 | 25,022,156.54 | 10,235,404.84 | 18,446,708.96 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.44 | 0.2 | 0.1 | 0.25 |
| (二)稀释每股收益 | 0.44 | 0.2 | 0.1 | 0.25 |
| 八、其他综合收益 | -561,524.46 | -207,233.14 | -66,176.78 | 672,703.34 |
| 归属于母公司股东的其他综合收益 | -561,524.46 | -207,233.14 | -66,176.78 | 672,703.34 |
| 九、综合收益总额 | 81,201,746.98 | 37,531,896.5 | 18,862,379.79 | 48,132,701.37 |
| 归属于母公司股东的综合收益总额 | 81,201,746.98 | 37,349,911.04 | 18,727,675.15 | 46,601,506.2 |
| 归属于少数股东的综合收益总额 | - | 181,985.46 | 134,704.64 | 1,531,195.17 |
| 公告日期 | 2025-10-29 | 2025-08-15 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |